Correction to: Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists’ and Urologists’ Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries Laura PanattoniMairead KearneyBrett Hauber Correction 14 June 2024
A Systematic Review of Methods for Estimating Productivity Losses due to Illness or Caregiving in Low- and Middle-Income Countries Ery SetiawanSarah A. Cassidy-SeyoumAngela Devine Systematic Review Open access 14 June 2024
NICE Approaches to Expert Opinion Evidence in Highly Specialised Technologies: Time to Change? Evidence Assessment Group Perspective Najmeh MoradiNicole O’ConnorGurdeep S. Sagoo Commentary 11 June 2024
Comparing Generic Paediatric Health-Related Quality-of-Life Instruments: A Dimensionality Assessment Using Factor Analysis Mina BahrampourRenee Jonesthe QUOKKA (Quality of Life in Kids: Key Evidence for Decision Makers in Australia) Team Original Research Article Open access 31 May 2024 Pages: 81 - 94
A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies Paul TappendenOrla Hardimanthe ALS-CarE Study Group Original Research Article 31 May 2024
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment Frederick McElweeAnthony Newall Leading Article Open access 31 May 2024
A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses Ramesh LamsalE. Ann YehWendy J. Ungar Systematic Review Open access 31 May 2024
Examining the Effect of Depicting a Patient Affected by a Negative Reimbursement Decision in Healthcare on Public Disagreement with the Decision Anne de BruijnMats van DonVivian Reckers-Droog Original Research Article Open access 26 May 2024
Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective Takao TakeshimaFumihiko SakaiMartijn J. H. G. Simons Original Research Article Open access 21 May 2024 Pages: 811 - 822
Bayesian Meta-Analysis of Health State Utility Values: A Tutorial with a Practical Application in Heart Failure Joseph Alvin Ramos SantosRobert GrantGian Luca Di Tanna Practical Application Open access 20 May 2024 Pages: 721 - 735
A Prototype Software Framework for Transferable Computational Health Economic Models and Its Early Application in Youth Mental Health Matthew P. HamiltonCaroline GaoCathrine Mihalopoulos Practical Application Open access 20 May 2024
Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework Askal Ayalew AliAmit KulkarniVakaramoko Diaby Original Research Article Open access 17 May 2024
Cost-of-Illness of Skin Cancer: A Systematic Review Annick MeertensLaura Van CoileIsabelle Hoorens Systematic Review 16 May 2024 Pages: 751 - 765
A Comparison of the Psychometric Properties of the EQ-5D-Y-3L and EQ-5D-Y-5L Using Paediatric Multi-Instrument Comparison (P-MIC) Study Data Mina BahrampourNancy DevlinOn behalf of the QUOKKA (Quality of Life in Kids: Key Evidence for Decision Makers in Australia) Team Original Research Article Open access 15 May 2024 Pages: 95 - 111
Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs? Salah Ghabri Editorial 11 May 2024
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review Clazinus VeijerMarinus H. van HulstAntoinette D.I. van Asselt Systematic Review Open access 10 May 2024 Pages: 633 - 647
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children Wendy J. UngarMichael Herdman Editorial Open access 09 May 2024 Pages: 3 - 8
Market Transparency in Medicine Pricing: Pathways to Fair Pricing João L. Carapinha Commentary 09 May 2024 Pages: 611 - 614
Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective Mirre ScholteBram RamaekersNigel Armstrong Commentary Open access 08 May 2024
Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective Bradley M. SugdenSabine E. GrimmWillem J. A. Witlox Commentary Open access 07 May 2024 Pages: 615 - 618
Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States William L. HerringMeghan E. GallagherBiree Andemariam Original Research Article Open access 29 April 2024 Pages: 693 - 714
Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature Gemma E. ShieldsPaul ClarksonLinda M. Davies Review Article 27 April 2024 Pages: 737 - 749
Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review Tobias Sydendal GrandShijie RenPraveen Thokala Review Article Open access 14 April 2024 Pages: 619 - 631
A Blueprint for Multi-use Disease Modeling in Health Economics: Results from Two Expert-Panel Consultations Junfeng WangXavier Pouwelsthe Dutch multi-use disease modeling consortium Original Research Article Open access 13 April 2024 Pages: 797 - 810
Barriers and Facilitators of Using R for Decision Analytic Modeling in Health Technology Assessment: Focus Group Results Yanara MarksJeffrey S. HochPetros Pechlivanoglou Original Research Article 12 April 2024 Pages: 783 - 795
Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective? Anna KensethDominika KantorovaJørn Evert Jacobsen Original Research Article 07 April 2024 Pages: 679 - 691
Value of Information for Clinical Trial Design: The Importance of Considering All Relevant Comparators Anna HeathGianluca BaioNicky J. Welton Practical Application Open access 07 April 2024 Pages: 479 - 486
Childhood Transitions Between Weight Status Categories: Evidence from the UK Millennium Cohort Study Olu OnyimaduNerys M. AstburyMara Violato Original Research Article Open access 03 April 2024 Pages: 649 - 661
Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments Jen-Yu Amy ChangJames B. ChilcottNicholas R. Latimer Review Article 01 April 2024 Pages: 487 - 506
Quality Appraisal in Systematic Literature Reviews of Studies Eliciting Health State Utility Values: Conceptual Considerations Muchandifunga Trust MuchadeyiKarla Hernandez-VillafuerteMichael Schlander Original Research Article Open access 29 March 2024 Pages: 767 - 782
Developing a Program Costs Checklist of Digital Health Interventions: A Scoping Review and Empirical Case Study Zareen Abbas KhanKristian KidholmVidar Halsteinli Original Research Article Open access 26 March 2024 Pages: 663 - 678
Correction: Comparing the Psychometric Performance of Generic Paediatric Health‑Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression Rachel O’LoughlinRenee Jonesin collaboration with the Quality Of Life in Kids: Key evidence to strengthen decisions in Australia (QUOKKA) Project Team Correction Open access 25 March 2024 Pages: 79 - 79
Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling Isaac Corro RamosTalitha FeenstraMaiwenn Al Short Communication Open access 18 March 2024 Pages: 715 - 719
Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review Angie RaadMaria RizzoLuis Hernandez Systematic Review Open access 15 March 2024 Pages: 527 - 568
Reply to Comment on “A Framework for Fair Pricing of Medicines” Mike Paulden Letter to the Editor 13 March 2024 Pages: 607 - 609
Comment on: A Framework for the Fair Pricing of Medicines Zaheer-Ud-Din Babar Letter to the Editor 13 March 2024 Pages: 605 - 606
Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists’ and Urologists’ Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries Laura PanattoniMairead KearneyBrett Hauber Original Research Article 12 March 2024
Economic Evaluations of Treatments for Duchenne Muscular Dystrophy: The Caregiver QALY Trap Erik LandfeldtHera Sandhu Commentary 05 March 2024 Pages: 475 - 478
Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary Anna NiklMathieu F. JanssenFanni Rencz Original Research Article Open access 28 February 2024 Pages: 583 - 603
Exploring the Use of Pictorial Approaches in the Development of Paediatric Patient-Reported Outcome Instruments: A Systematic Review Christine Mpundu-KaambwaNorma B. Bulamuthe Quality of Life in Kids: Key Evidence for Decision Makers in Australia (QUOKKA) project team Systematic Review Open access 13 February 2024 Pages: 9 - 37
Content Comparison of Quality-of-Life Instruments Used in Economic Evaluations of Sleep Disorder Interventions: A Systematic Review Billingsley KaambwaTaylor-Jade WoodsDanny J. Eckert Systematic Review Open access 10 February 2024 Pages: 507 - 526
Comparing the Psychometric Performance of Generic Paediatric Health-Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression Rachel O’LoughlinRenee Jonesin collaboration with the Quality Of Life in Kids: Key evidence to strengthen decisions in Australia (QUOKKA) project team Original Research Article Open access 08 February 2024 Pages: 57 - 77
Incorporating Real Option Value in Valuing Innovation: A Way Forward Meng LiLouis P. Garrison Original Research Article Open access 04 February 2024
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA Shih-Wen LinSheila ShapouriMatthew Matasar Original Research Article Open access 01 February 2024 Pages: 569 - 582
Psychometric Properties of Child Health Utility 9D (CHU9D) Proxy Version Administered to Parents and Caregivers of Children Aged 2–4 Years Compared with Pediatric Quality of Life Inventory™ (PedsQL) Xiuqin XiongNatalie CarvalhoKim Dalziel Original Research Article Open access 27 January 2024 Pages: 147 - 161
An Investigation of Inter-Rater and Intra-Proxy Agreement in Measuring Quality of Life of Children in the Community Using the EQ-5D-Y-3L Diana KhannaJyoti Khadkain collaboration with the Quality of Life in Kids: Key Evidence to Strengthen Decisions in Australia (QUOKKA) Project Team Original Research Article Open access 27 January 2024 Pages: 113 - 128
The Burden of Type 2 Diabetes on the Productivity and Economy in Sub-Saharan Africa: A Life Table Modelling Analysis from a South African Perspective Assegid HelleboAndre P. KengneOlufunke Alaba Original Research Article Open access 24 January 2024 Pages: 463 - 473
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States Anita J. BroganAshley E. DavisAlan K. Oglesby Original Research Article Open access 24 January 2024 Pages: 447 - 461